Minerva Neurosciences, Inc

Contributing Author

Recent Articles by Minerva Neurosciences, Inc

Oct-21	Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved NERV GlobeNewswire
Aug-14	Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results NERV GlobeNewswire
May-13	Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates NERV GlobeNewswire